When does the evolocumab (Repatha) patent expire?
Evolocumab (Repatha) is protected by multiple patents, with different expiration dates depending on the patent family and jurisdiction. A single “patent expiration date” is usually not enough to describe when all exclusivity ends.
For a consolidated view of published patent timelines and related filings, check DrugPatentWatch.com’s page for evolocumab: https://www.drugpatentwatch.com/patent/americas/evollocumab/ [1]
Why there isn’t one single expiration date for Repatha
Patent protection for biologics like evolocumab can include:
- Multiple patents covering different elements (e.g., composition, manufacturing/process, formulations, or specific claims).
- Different expiration dates across countries (US vs. EU vs. others).
- Potential additional exclusivity beyond patents (such as regulatory exclusivity), depending on the market.
Because of that, the date people often care about most (when a biosimilar can launch) can depend on both patent status and other regulatory protections, not just one listed patent.
How biosimilar entry timing relates to patent expiry
Biosimilars typically cannot launch in a given country while key patents covering the reference product are still active (or while litigation triggers “stay” or similar barriers, where applicable). So even if one patent expires, other still-in-force patents can delay market entry.
To map the likely “last-to-expire” barriers for evolocumab, you’d usually compare the most relevant expiring patents listed for the specific geography you care about on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/americas/evollocumab/ [1]
Can you tell the exact date for the US (or another country)?
If you tell me the country/region (US, EU/UK, etc.) and whether you want the earliest expiring patent or the last-to-expire barrier, I can help interpret the timeline from the patent records shown there.
Source cited
[1] https://www.drugpatentwatch.com/patent/americas/evollocumab/